We retrieved the expression values from CCLE for the group of proteins that mark for immune response and calculated the linear regression against the sensitivity values for each drug in a panel of 20 HER2-positive breast cancer cell lines (ANOVA p-value < 0.01). Here, ERBB2 is linked to breast carcinoma.